We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

0.02% more ownership

Funds ownership: 0.79% → 0.82% (+0.02%)

0% more funds holding

Funds holding: 115 → 115 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

23% less capital invested

Capital invested by funds: $232M → $179M (-$53.7M)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $486K

Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
45
Reduced
30
Closed
20
Calls
$1K
Puts
$486K
Net Calls
-$485K
Net Calls Change
+$244K

Top Buyers

1
BI
BVF Inc
California
+$10.4M
2
BlackRock
BlackRock
New York
+$5.26M
3
PM
Prosight Management
Texas
+$4.74M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$3.95M
5
American Century Companies
American Century Companies
Missouri
+$2.57M

Top Sellers

1
O
OrbiMed
New York
-$14.3M
2
Morgan Stanley
Morgan Stanley
New York
-$5.2M
3
Millennium Management
Millennium Management
New York
-$4.42M
4
EI
EAM Investors
California
-$3.56M
5
AL
AJO LP
Pennsylvania
-$2.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$27.1M +$10.4M +21,928 +49%
O
2
OrbiMed
New York
$15.9M -$14.3M -30,125 -43%
BlackRock
3
BlackRock
New York
$13.6M +$5.26M +11,055 +49%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$10.8M +$3.95M +8,300 +45%
TCM
5
Tekla Capital Management
Massachusetts
$10.6M – – –
ACM
6
Aquilo Capital Management
California
$10M +$11.7M +24,689 New
Renaissance Technologies
7
Renaissance Technologies
New York
$7.72M -$42.8K -90 -0.5%
PM
8
Prosight Management
Texas
$6.89M +$4.74M +9,953 +141%
Millennium Management
9
Millennium Management
New York
$5.48M -$4.42M -9,283 -41%
Arrowstreet Capital
10
Arrowstreet Capital
Massachusetts
$5.16M -$70.4K -148 -1%
SFM
11
Sphera Funds Management
Israel
$4.27M +$254K +533 +5%
SSA
12
Schonfeld Strategic Advisors
New York
$4.2M -$11.9K -25 -0.2%
OFM
13
Omega Fund Management
Massachusetts
$3.95M – – –
State Street
14
State Street
Massachusetts
$3.79M +$967K +2,033 +28%
Goldman Sachs
15
Goldman Sachs
New York
$3.54M +$190K +400 +5%
LOAMU
16
Lombard Odier Asset Management (USA)
New York
$2.86M +$297K +625 +10%
American Century Companies
17
American Century Companies
Missouri
$2.37M +$2.57M +5,391 +1,182%
OAM
18
Oxford Asset Management
United Kingdom
$1.93M +$364K +764 +19%
Northern Trust
19
Northern Trust
Illinois
$1.79M -$13.3K -28 -0.6%
BIM
20
Bogle Investment Management
Massachusetts
$1.69M +$1.42M +2,975 +248%
Vanguard Group
21
Vanguard Group
Pennsylvania
$1.65M +$786K +1,652 +68%
RPAM
22
Rhenman & Partners Asset Management
Sweden
$1.52M – – –
Geode Capital Management
23
Geode Capital Management
Massachusetts
$1.46M +$203K +426 +13%
TCIM
24
TIAA CREF Investment Management
New York
$1.43M -$893K -1,877 -35%
WCM
25
Wedge Capital Management
North Carolina
$1.38M +$836K +1,757 +107%
1
2 3 4 5

PVLA Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.

Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
  • The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q2 2018.